JP2023531722A5 - - Google Patents
Info
- Publication number
- JP2023531722A5 JP2023531722A5 JP2022579956A JP2022579956A JP2023531722A5 JP 2023531722 A5 JP2023531722 A5 JP 2023531722A5 JP 2022579956 A JP2022579956 A JP 2022579956A JP 2022579956 A JP2022579956 A JP 2022579956A JP 2023531722 A5 JP2023531722 A5 JP 2023531722A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antibody molecule
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043558P | 2020-06-24 | 2020-06-24 | |
| US63/043,558 | 2020-06-24 | ||
| US202063091002P | 2020-10-13 | 2020-10-13 | |
| US63/091,002 | 2020-10-13 | ||
| US202163136950P | 2021-01-13 | 2021-01-13 | |
| US63/136,950 | 2021-01-13 | ||
| US202163195527P | 2021-06-01 | 2021-06-01 | |
| US63/195,527 | 2021-06-01 | ||
| PCT/US2021/038924 WO2021262999A1 (en) | 2020-06-24 | 2021-06-24 | Antibody molecules to april and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531722A JP2023531722A (ja) | 2023-07-25 |
| JP2023531722A5 true JP2023531722A5 (cg-RX-API-DMAC7.html) | 2024-06-24 |
Family
ID=77022225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579956A Pending JP2023531722A (ja) | 2020-06-24 | 2021-06-24 | Aprilに対する抗体分子およびその使用 |
Country Status (11)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170145086A1 (en) | 2015-11-25 | 2017-05-25 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| AU2023262513A1 (en) * | 2022-04-25 | 2024-12-05 | Visterra, Inc. | Antibody molecules to april and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| US20170145086A1 (en) * | 2015-11-25 | 2017-05-25 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| CA3032820A1 (en) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
-
2021
- 2021-06-24 KR KR1020237002087A patent/KR20230042273A/ko active Pending
- 2021-06-24 AU AU2021297315A patent/AU2021297315A1/en active Pending
- 2021-06-24 CA CA3187823A patent/CA3187823A1/en active Pending
- 2021-06-24 BR BR112022026639A patent/BR112022026639A2/pt unknown
- 2021-06-24 EP EP21745524.5A patent/EP4172206A1/en active Pending
- 2021-06-24 MX MX2022016591A patent/MX2022016591A/es unknown
- 2021-06-24 TW TW110123219A patent/TW202216195A/zh unknown
- 2021-06-24 PH PH1/2023/550198A patent/PH12023550198A1/en unknown
- 2021-06-24 WO PCT/US2021/038924 patent/WO2021262999A1/en not_active Ceased
- 2021-06-24 JP JP2022579956A patent/JP2023531722A/ja active Pending
-
2024
- 2024-09-27 US US18/899,795 patent/US20260116988A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI859164B (zh) | 利用抗fcrn抗體治療葛瑞夫茲氏眼病之方法 | |
| Wallach et al. | Advances in the treatment of neuromyelitis optica spectrum disorder | |
| JP2023548858A5 (cg-RX-API-DMAC7.html) | ||
| EP3487881B1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| Van Doorn | Treatment of Guillain‐Barré syndrome and CIDP | |
| JP2022515770A5 (cg-RX-API-DMAC7.html) | ||
| Prasad et al. | Intravenous immunoglobulin in pediatrics: A review | |
| JP2025514142A5 (cg-RX-API-DMAC7.html) | ||
| US20230049011A1 (en) | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies | |
| KR20240117655A (ko) | 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임 | |
| WO2019020069A1 (zh) | 一种sost抗体药物组合物及其用途 | |
| JP2019519584A5 (cg-RX-API-DMAC7.html) | ||
| WO2022090169A1 (en) | Method of safe administration of anti-tau antibody | |
| US12358977B2 (en) | Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the IL-20R | |
| CA2946929A1 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| Lozano-Blasco et al. | A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG | |
| Ponleitner et al. | Treatment of neuromyelitis optica spectrum disorder: revisiting the complement system and other aspects of pathogenesis | |
| JP2021147383A (ja) | アトピー性皮膚炎及び関連障害を処置するための方法 | |
| US20240409631A1 (en) | Aqueous formulations of an anti-cd22 antibody and uses thereof | |
| WO2020108621A1 (zh) | 一种cd40抗体药物组合物及其用途 | |
| JP2024522620A5 (cg-RX-API-DMAC7.html) | ||
| JP2023534576A5 (cg-RX-API-DMAC7.html) | ||
| Ramesh et al. | Therapeutic uses of intravenous immunoglobulin (IVIG) in children | |
| TW202114734A (zh) | Il-17拮抗劑治療自身免疫疾病的方法 | |
| Dhandha et al. | Treatment of selective antibody deficiency with IVIG resulting in decreased frequency of streptococcal infection and improvement of guttate psoriasis |